– Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 – – Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019 – SAN DIEGO --(BUSINESS WIRE)--Mar.

SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2020-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila

SAN DIEGO --(BUSINESS WIRE)--Feb. 13, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will

SAN DIEGO --(BUSINESS WIRE)--Jan. 23, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the